Compare Dyne Therapeutics Inc. Common Stock (DYN) vs PDD Holdings Inc. American Depositary Shares (PDD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs PDD Holdings Inc. American Depositary Shares — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while PDD Holdings Inc. American Depositary Shares trades at $80 (market cap $116.66B). The key difference: PDD Holdings Inc. American Depositary Shares is far larger — about 40.8× Dyne Therapeutics Inc. Common Stock's market cap, and PDD Holdings Inc. American Depositary Shares is more actively traded (9,095,378 versus 3,341,579). Which is the better fit depends on your goals.
| DYN | PDD | |
|---|---|---|
Market Cap | $2.86B | $116.66B |
Volume | 3,341,579 | 9,095,378 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $138.13 |
52-Week Low | $14.60 | $73.30 |
Typical Hold Time | 0 Days | — |
Enterprise Value | $2.18B | $49.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
PDD Holdings trades at $81.96, up 1.29% with a bullish technical signal despite recent earnings volatility. The stock shows strong fundamentals with a P/E of 8.81 and robust profitability margins (net income margin 20.43%). Recent news highlights investor attention and the company's major investment cycle while facing regulatory and competitive pressures.
The outlook remains cautiously optimistic with a $99.13 consensus price target, though risks include trade policy impacts and execution challenges from PDD's shift to an asset-heavy model. Earnings misses in recent quarters and moderating revenue growth warrant close monitoring for sustained investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About PDD Holdings Inc. American Depositary Shares
PDD Holdings is a multinational commerce group that owns and operates a portfolio of businesses. Its sourcing, logistics, and fulfillment network supports those businesses and their commerce operations.
Read more on PDD →
